<DOC>
	<DOCNO>NCT00044577</DOCNO>
	<brief_summary>A 48-week study investigate safety effectiveness new compact formulation two already FDA-approved anti-HIV drug subject already receive treatment HIV infection .</brief_summary>
	<brief_title>New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects</brief_title>
	<detailed_description>A phase III , randomize , open-label , parallel , multicenter study evaluate treatment fixed-dose combination abacavir/lamivudine ( 600mg/300mg ) once-daily versus abacavir ( 300mg ) twice-daily lamivudine ( 300mg ) once-daily combination tenofovir once-daily new PI NNRTI 48 week ART-experienced HIV-1 infected patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Antiretroviral therapy ( ART ) experience currently receive stable regimen contain 3 nucleoside reverse transcriptase inhibitor ( NRTIs ) , 2 NRTIs plus protease inhibitor ( PI ) nonnucleoside reverse transcriptase inhibitor ( NNRTI ) least 3 month ( significant ART modification least 3 month ART change anticipate Screening initiation study therapy ) . Patients must naive tenofovir . HIV1 RNA level &gt; 1000 copies/ml least one occasion within 21 day study entry . A CD4 cell count &gt; 50 cells/mm3 . Specified viral genotype . Pregnant breastfeed woman . Has active diagnosis AIDS . Additional qualify criterion determine physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>HIV-1 Abacavir Lamivudine Tenofovir</keyword>
</DOC>